What is the potential breakthrough?
What is the potential impact on Europe’s healthcare systems?
As remyelination therapies are likely to be used as add-on treatments or in combination with other existing therapies, they may generate incremental costs for healthcare systems. However, social services account for >40% of total HCS costs related to MS. Through improving the physical condition of MS patients, remyelinating therapies will reduce their need for social services, thus bringing savings to public budgets. Assuming remyelinating drugs will reduce the disability by 25% in 15% of MS patients, they will generate ~€124 million savings across the Europe.
Download the full IQVIA/EFPIA Pipeline Review 2021
Disease never takes a break, so neither do we. We won’t rest until people around the world see a brighter tomorrow.Read more